Literature DB >> 26140235

Antileukemia T-cell responses in CLL - We don't need no aberration.

Daniel J Kowalewski1, Stefan Stevanovic2, Hans-Georg Rammensee2, Juliane S Stickel3.   

Abstract

Effective antigen-specific cancer immunotherapy requires exact knowledge of tumor-associated epitopes that can act as rejection antigens. Although the current paradigm views mutation-derived neoantigens as the most promising targets, we have recently demonstrated that leukemia-specific T-cell responses associated with survival benefit in CLL patients target a panel of non-mutated tumor-associated antigens.

Entities:  

Keywords:  cancer immunotherapy; chronic lymphocytic leukemia; neoantigen; tumor-associated antigen

Year:  2015        PMID： 26140235      PMCID： PMC4485708          DOI： 10.1080/2162402X.2015.1011527

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  7 in total

1.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

2.  HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).

Authors:  Daniel J Kowalewski; Heiko Schuster; Linus Backert; Claudia Berlin; Stefan Kahn; Lothar Kanz; Helmut R Salih; Hans-Georg Rammensee; Stefan Stevanovic; Juliane Sarah Stickel
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

3.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

4.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

Authors:  Nienke van Rooij; Marit M van Buuren; Daisy Philips; Arno Velds; Mireille Toebes; Bianca Heemskerk; Laura J A van Dijk; Sam Behjati; Henk Hilkmann; Dris El Atmioui; Marja Nieuwland; Michael R Stratton; Ron M Kerkhoven; Can Kesmir; John B Haanen; Pia Kvistborg; Ton N Schumacher
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

5.  Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface.

Authors:  Andreas O Weinzierl; Claudia Lemmel; Oliver Schoor; Margret Müller; Tobias Krüger; Dorothee Wernet; Jörg Hennenlotter; Arnulf Stenzl; Karin Klingel; Hans-Georg Rammensee; Stefan Stevanovic
Journal:  Mol Cell Proteomics       Date:  2006-10-29       Impact factor: 5.911

6.  Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Authors:  C Berlin; D J Kowalewski; H Schuster; N Mirza; S Walz; M Handel; B Schmid-Horch; H R Salih; L Kanz; H-G Rammensee; S Stevanović; J S Stickel
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

7.  Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.

Authors:  Paul F Robbins; Yong-Chen Lu; Mona El-Gamil; Yong F Li; Colin Gross; Jared Gartner; Jimmy C Lin; Jamie K Teer; Paul Cliften; Eric Tycksen; Yardena Samuels; Steven A Rosenberg
Journal:  Nat Med       Date:  2013-05-05       Impact factor: 53.440
  7 in total
  8 in total

1.  HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Authors:  Annika Nelde; Daniel J Kowalewski; Linus Backert; Heiko Schuster; Jan-Ole Werner; Reinhild Klein; Oliver Kohlbacher; Lothar Kanz; Helmut R Salih; Hans-Georg Rammensee; Stefan Stevanović; Juliane S Walz
Journal:  Oncoimmunology       Date:  2018-02-14       Impact factor: 8.110

2.  Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.

Authors:  D J Kowalewski; S Walz; L Backert; H Schuster; O Kohlbacher; K Weisel; S M Rittig; L Kanz; H R Salih; H-G Rammensee; S Stevanović; J S Stickel
Journal:  Blood Cancer J       Date:  2016-04-08       Impact factor: 11.037

3.  A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.

Authors:  Linus Backert; Daniel Johannes Kowalewski; Simon Walz; Heiko Schuster; Claudia Berlin; Marian Christoph Neidert; Mirle Schemionek; Tim H Brümmendorf; Vladan Vucinic; Dietger Niederwieser; Lothar Kanz; Helmut Rainer Salih; Oliver Kohlbacher; Katja Weisel; Hans-Georg Rammensee; Stefan Stevanovic; Juliane Sarah Walz
Journal:  Oncotarget       Date:  2017-07-04

4.  ImmunoNodes - graphical development of complex immunoinformatics workflows.

Authors:  Benjamin Schubert; Luis de la Garza; Christopher Mohr; Mathias Walzer; Oliver Kohlbacher
Journal:  BMC Bioinformatics       Date:  2017-05-08       Impact factor: 3.169

5.  The Genomic Landscape of Antigenic Targets for T Cell-Based Leukemia Immunotherapy.

Authors:  Marie-Pierre Hardy; Krystel Vincent; Claude Perreault
Journal:  Front Immunol       Date:  2019-12-20       Impact factor: 7.561

Review 6.  T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.

Authors:  Elisavet Vlachonikola; Kostas Stamatopoulos; Anastasia Chatzidimitriou
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

7.  A tissue-based draft map of the murine MHC class I immunopeptidome.

Authors:  Heiko Schuster; Wenguang Shao; Tobias Weiss; Patrick G A Pedrioli; Patrick Roth; Michael Weller; David S Campbell; Eric W Deutsch; Robert L Moritz; Oliver Planz; Hans-Georg Rammensee; Ruedi Aebersold; Etienne Caron
Journal:  Sci Data       Date:  2018-08-07       Impact factor: 6.444

8.  Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer.

Authors:  Qingda Meng; Davide Valentini; Martin Rao; Carlos Fernández Moro; Georgia Paraschoudi; Elke Jäger; Ernest Dodoo; Elena Rangelova; Marco Del Chiaro; Markus Maeurer
Journal:  Br J Cancer       Date:  2018-10-31       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.